SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group (CAR) is driving intense market conversation due to a historic short squeeze fueled by highly concentrated ownership among two major hedge funds, which effectively control the majority of the float and have limited available shares for short covering. Community members are actively debating the sustainability of this parabolic move, with many highlighting extreme technical indicators, high volatility, and potential regulatory scrutiny, while retail traders remain split between chasing the momentum and betting on an inevitable correction.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is rallying on massive volume as investors react to a pivotal executive interview confirming production orders and scaling manufacturing for AI hyperscaler demand. The community is actively dismissing recent short-seller reports and debating the company's transition from speculative tech to a commercial revenue story, while speculating on the impact of potential index inclusion and strategic partnerships.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is seeing strong momentum as institutional interest shifts toward a catch-up trade, supported by bullish analyst price target hikes and major hyperscaler commitments from Meta and OpenAI. The community remains highly active, debating the stock's potential for sustained growth against its current valuation and the ongoing battle between hardware and software-driven AI returns.

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Kyverna Therapeutics Inc.

Kyverna Therapeutics is trending as investors react to positive topline results from its registrational phase two trial of miv-cel for stiff person syndrome, which showed significant clinical benefits and a clean safety profile. The community is actively discussing the potential for a near-term buyout or partnership, fueled by the company's best-in-class CAR-T pipeline, experienced management, and its path toward a biologics license application.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

Direxion Daily Semiconductor Bull 3X Shares (SOXL) is experiencing extreme volatility and rapid gains, fueled by persistent AI-driven optimism, ongoing semiconductor strength, and a market environment that continues to defy bearish expectations. While some traders are riding the aggressive momentum to new highs, a vocal segment of the community remains cautious, citing concerns over potential overextension, the structural risks of leveraged ETFs in choppy conditions, and uncertainty regarding geopolitical tensions.

Infinite Money Glitch ($IMG) is revolutionizing DeFi on Solana by leveraging the Token2022 program's advanced tax extension capabilities to create a truly innovative reward system for token holders.  At its core, $IMG implements a seamless 5% tax on all transactions - whether buying, selling, or transferring tokens. This tax is automatically collected and distributed to holders in SOL, creating a sustainable passive income stream for the community. 4.5% of the tax gets sent to holders, while .5% gets sent to an Infrastructure wallet to help with development, marketing and general infrastructure.  What sets $IMG apart is its implementation of Solana's Token2022 program, enabling automated and efficient reward distribution without relying on external smart contracts.

Infinite Money Glitch

The community surrounding $IMG is rallying behind the token's passive Solana rewards and deflationary mechanisms, framing it as a 'battle-tested' utility play that has survived significant market adversity. Investors are actively discussing the protocol's technological resilience and upcoming milestones, viewing current entry levels as a strategic opportunity to accumulate ahead of a potential supply shock.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is experiencing significant momentum driven by investor enthusiasm for its gallium nitride power technology, which is increasingly viewed as a critical component for AI data center efficiency. While bulls point to high-profile industry partnerships and long-term demand for AI infrastructure, the stock remains a flashpoint for debate, as skeptics warn that current price action is fueled by sentiment and short-term speculative positioning rather than immediate earnings-based fundamentals.

OpenGradient

OpenGradient is attracting significant momentum as traders view it as an early-stage opportunity and the next potential breakout candidate following recent market runners. The community is actively discussing high-volume liquidity and the potential for increased public awareness as they coordinate efforts to boost the asset's visibility.

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

Phathom Pharmaceuticals Inc

Phathom Pharmaceuticals is currently generating significant community buzz, driven by optimistic analyst revisions and anticipation for profitability by 2026 as its GI-focused commercial strategy gains traction. Investors are actively discussing the company as a prime acquisition target for Big Pharma, fueled by a combination of high prescription growth, recent patent exclusivity protections, and a tightening expense profile that signals strong long-term value creation.

Brand Engagement Network, Inc. engages in the provision of conversational artificial intelligence assistants with the purpose of transforming engagement and analytics for businesses through security-focused, multimodal communication and human-like artificial intelligence assistants. The firm is also involved in delivering highly personalized, multi-modal artificial intelligence engagement with a focus on industries where there is a massive workforce gap and an opportunity to transform how consumers engage with networks, providers, and brands. The company is founded on March 14, 2024 and is headquartered in Greenwood Village, CO.

Brand Engagement Network Inc

Brand Engagement Network is generating significant community buzz due to its aggressive pivot toward commercializing agentic AI solutions, with retail investors closely monitoring upcoming earnings and potential enterprise licensing partnerships as catalysts for a major price move. The stock is currently experiencing high volatility driven by extreme cost-to-borrow rates and community speculation regarding a potential short squeeze, as bullish holders emphasize long-term growth prospects over immediate trading fluctuations.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Metagenomi, Inc. (NASDAQ:MGX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Metagenomi, Inc. (NASDAQ:MGX - Get Free Report) has been given an average recommendation of "Moderate Buy" by the five ratings firms that are presently covering the stock, MarketBeat reports. One...

Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? PR Newswire NEW...

Metagenomi (MGX) to Release Earnings on Wednesday

Metagenomi (NASDAQ:MGX) will be releasing its Q4 2025 earnings before the market opens on Wednesday, April 1. (View Earnings Report at...

Wall Street Zen Downgrades Metagenomi (NASDAQ:MGX) to Sell

Wall Street Zen cut Metagenomi from a "hold" rating to a "sell" rating in a report on Saturday...

Metagenomi, Inc. (NASDAQ:MGX) Receives Average Rating of "Moderate Buy" from Brokerages

Shares of Metagenomi, Inc. (NASDAQ:MGX - Get Free Report) have earned an average recommendation of "Moderate Buy" from the five research firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, three have issued a buy rating...

Metagenomi (MGX) Projected to Post Quarterly Earnings on Monday

Metagenomi (NASDAQ:MGX) will be releasing its Q4 2025 earnings before the market opens on Monday, March 16. (View Earnings Report at...

Metagenomi Therapeutics (MGX) Reports Q4 Loss, Misses Revenue Estimates

Metagenomi Therapeutics (MGX) delivered earnings and revenue surprises of -4.35% and -54.84%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Metagenomi, Inc. (NASDAQ:MGX) Sees Significant Drop in Short Interest

Metagenomi, Inc. (NASDAQ:MGX - Get Free Report) was the recipient of a large drop in short interest during the month of February. As of February 13th, there was short interest totaling 1,982,687...

Amphastar Pharmaceuticals (AMPH) Q4 Earnings and Revenues Lag Estimates

Amphastar (AMPH) delivered earnings and revenue surprises of -24.49% and -5.63%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Metagenomi, Inc. (NASDAQ:MGX) Given Consensus Rating of "Moderate Buy" by Analysts

Shares of Metagenomi, Inc. (NASDAQ:MGX - Get Free Report) have been given an average recommendation of "Moderate Buy" by the five ratings firms that are currently covering the company, MarketBeat...

Metagenomi Therapeutics, Inc. is a precision genetic medicines company, which engages in the business of developing next generation gene-editing technologies and therapies. Its business activities include developing gene edit­ing toolbox, ther­a­peu­tic focus, and processing discovery platform. The company was founded by Brian C. Thomas on September 16, 2016 and is headquartered in Emeryville, CA.

MGX
Metagenomi Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MGX News

MGXMetagenomi Inc.